The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

Yang, Jiaying; He, Jieyu; Yu, Miao; Li, Taishun; Luo, Lixia; Liu, Pei

doi:10.1097/md.0000000000005599

Cited by 8 publications

(12 citation statements)

References 56 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood disorders were more frequently reported in the control group. As anemia is frequently reported as a result of applied chemotherapy and/or targeted therapy [ 18 ] it could explain the increased rate in the control group. In addition, thromboembolic events and hemorrhage were documented for bevacizumab in combination with CTx [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, thromboembolic events and hemorrhage were documented for bevacizumab in combination with CTx [ 10 ]. Gastrointestinal adverse events have been reported to be increased in patients during mAb, targeted, or ICI therapy [ 9 , 10 , 11 , 18 ] and may explain the higher percentage of these events in the control group. Accordingly, as to diarrhea the incidence was reported to be elevated in combined CTx/mAb [ 11 ] and CTx/targeted therapy [ 18 ] compared to CTx alone.…”

Section: Discussionmentioning

confidence: 99%

“…It has repeatedly been reported that survival benefit of targeted therapy may come at the cost of toxicity potentiation when provided alone [ 8 ] or in combination with standard or chemotherapy [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. A plethora of studies have been published documenting, besides good clinical outcome, potentiation of toxicities in combination treatment of chemotherapy or standard therapy with mAbs, targeted treatment, or immunotherapy [ 9 , 10 , 11 , 18 ]. Due to the current importance, protocols and guidelines for the management of immune-related adverse events (AEs) due to immunotherapy have recently been published [ 19 , 20 , 21 , 22 , 23 , 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

et al. 2018

View full text Add to dashboard Cite

Background: Despite improvement of tumor response rates, targeted therapy may induce toxicities in cancer patients. Recent studies indicate amelioration of adverse events (AEs) by add-on mistletoe (Viscum album L., VA) in standard oncological treatment. The primary objective of this multicenter observational study was to determine the safety profile of targeted and add-on VA therapy compared to targeted therapy alone. Methods: Demographic and medical data were retrieved from the Network Oncology registry. Allocation to either control (targeted therapy) or combinational group (targeted/add-on VA) was performed. Safety-associated variables were evaluated by adjusted multivariable analyses. Results: The median age of the study population (n = 310) at first diagnosis was 59 years; 67.4% were female. In total, 126 patients (40.6%) were in the control and 184 patients (59.4%) in the combination group. Significant differences were observed between both groups with respect to overall AE frequency (χ2 = 4.1, p = 0.04) and to discontinuation of standard oncological treatment (χ2 = 4.8, p = 0.03) with lower rates in the combinational group (20.1%, 35% respectively) compared to control (30.2%, 60.5%, respectively). Addition of VA to targeted therapy significantly reduced the probability of oncological treatment discontinuation by 70% (Odds ratio (OR) 0.30, p = 0.02). Conclusions: Our results indicate a highly significant reduction of AE-induced treatment discontinuation in all-stage cancer patients when treated with VA in addition to targeted therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Guillermo et al first showed that hydroxylated pyrrolidine represents a SAH/MTA inhibitor and speculated that these compounds might be transitional analogs (76). However, inhibition of Pfs is fatal to cells because the accumulation of MTA and SAH is toxic to cells (77,78). Excess MTA levels in cells inhibit growth processes and DNA synthesis by indirectly preventing the synthesis of polyamines involved in these important processes (79,80).…”

Section: Target the Luxs/al-2 System: New Antibacterial Strategy For mentioning

confidence: 99%

Regulatory Mechanisms of the LuxS/AI-2 System and Bacterial Resistance

Wang

Liu

Grenier

et al. 2019

Antimicrob Agents Chemother

101

View full text Add to dashboard Cite

The quorum-sensing (QS) system is an intercellular cell-cell communication mechanism that controls the expression of genes involved in a variety of cellular processes and that plays critical roles in the adaption and survival of bacteria in their environment. The LuxS/AI-2 QS system, which uses AI-2 (autoinducer-2) as a signal molecule, has been identified in both Gram-negative and Gram-positive bacteria. As one of the important global regulatory networks in bacteria, it responds to fluctuations in the numbers of bacteria and regulates the expression of a number of genes, thus affecting cell behavior. We summarize here the known relationships between the LuxS/AI-2 system and drug resistance, discuss the inhibition of LuxS/AI-2 system as an approach to prevent bacterial resistance, and present new strategies for the treatment of drug-resistant pathogens.

show abstract

“…It is known that these drugs are given based on the performance status and age of the patient. Adverse effects are severe in several patients, and hospitalization is also necessary if these occur 20,21. In a recent study, it was proposed that a single agent or avoidance of platinum analogs for the elderly aged ≥70 years could be a solution 21.…”

Section: Discussionmentioning

confidence: 99%

Second-line afatinib administration in an elderly patient with squamous cell carcinoma

Hohenforst-Schmidt

Steinheimer

Benhassen³

et al. 2017

TCRM

View full text Add to dashboard Cite

IntroductionThe majority of cases of lung cancer are still diagnosed at a late stage. At this stage, palliative therapeutic options including nonspecific cytotoxic drugs, targeted therapy, or immunotherapy can be utilized. In 2016, immunotherapy was approved in Europe for squamous cell carcinoma and adenocarcinoma. Moreover, afatinib was also approved as second-line therapy for squamous cell carcinoma.Case reportThis article presents a case of a 76-year-old male with squamous cell carcinoma who received nab-paclitaxel as first-line therapy, and his treatment was switched to the tyrosine kinase inhibitor afatinib (40 mg) after disease progression with left lung atelectasis. After receiving afatinib for only 28 days, the atelectasis resolved. No adverse effects were observed from the afatinib therapy.DiscussionIn this case, afatinib 40 mg proved to be an effective alternative treatment for an elderly patient. Treatment choice should be based on the performance status of the patient, cost-effectiveness, and drug treatment guidelines.

show abstract

The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC)

Abstract: Supplemental Digital Content is available in the text

Cited by 8 publications

References 56 publications

Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

Clinical Safety of Combined Targeted and Viscum album L. Therapy in Oncological Patients

Regulatory Mechanisms of the LuxS/AI-2 System and Bacterial Resistance

Second-line afatinib administration in an elderly patient with squamous cell carcinoma

Contact Info

Product

Resources

About